PRESS RELEASE FROM
This press release is copyrighted to the journal Neuropsychopharmacology. Its use is granted only for journalists and news media receiving it directly from the Nature Publishing Group.
PLEASE CITE NEUROPSYCHOPHARMACOLOGY
AND THE NEUROPSYCHOPHARMACOLOGY
WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO http://www.nature.com/npp
Gene alteration affects cannabis-induced psychosis in adolescent mice
While there is a well-recognized association between cannabis use and psychotic illness, the mechanism that confers individual risk is not yet fully understood. Adolescent male mice are particularly susceptible to the psychosis-like effects of cannabis, reports a study published online this week in Neuropsychopharmacology, indicating that age at exposure and genotype are important factors. The underlying mechanism appears to involve variation in the gene for catechol-O-methyltransferase (COMT), which breaks down dopamine in the brain.
Colm O'Tuathaigh and colleagues subjected mice lacking the COMT gene to chronic THC exposure - a component of cannabis already thought to be involved in psychosis - during
either adolescence or adulthood. Their adult behavioral phenotypes were then measured and assessed for psychosis-like symptoms. Adolescent THC exposure in mice lacking the COMT gene modified exploratory activity and spatial working memory, together with anxiety-related behaviors, particularly in male mice. Each of these behaviors is associated with brain areas known to play a role in psychosis.
These findings indicate a genetic factor that, together with developmental factors, contributes to the vulnerability of adolescent cannabis users to psychosis. The authors caution, however, that further studies are needed to clarify the overall risk for psychosis in human consumers of cannabis.
Colm O'Tuathaigh (Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland) Tel: +35 31 402 2377; E-mail: firstname.lastname@example.org
Diane Drexler (Neuropsychopharmacology, Nashville, TN, USA) Tel: +1 615 324 2371; E-mail: email@example.com